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Abstract
In this paper we investigate the valuation and optimal timing of
the launch of two complementary/substitute products (or projects),
one of which is a pilot product. As a ﬁrst step, we study the problem
from a strategic point of view and analyze the ability of the pilot
product per se to create shareholder value. Next we provide a model
to evaluate the option to launch the pilot product in order to create
the option to launch the key product.
The model is designed to analyze the value of the pilot product and
the optimal timing to invest as functions of the degree of complemen-
tarity/substitutability among the two products. As a speciﬁcation, we
analyze under what conditions it is worth investing in a pilot prod-
uct with a negative NPV, whose option to invest is worthless due to
perfect competition.
The pilot product and the key product are driven by two diﬀerent
but correlated sources of uncertainty. The case is enriched by the pres-
ence of a patent on the key product and by the related consideration
of a change in the competition due to patent expiry. By resorting to
numerical analysis, we evaluate the embedded options and determine
the optimal investment policy for both products.
Our analysis allows us to capture the value of the options to in-
vest in both the key and pilot products (as a compound option) and
shows how the investment decision is aﬀected by a higher correlation
among products and a higher degree of substitutability. The major
outcome of the model is that a higher correlation and a higher degree
of substitutability among products increase the option value and ex-
pand the investment thresholds of the whole investment project, thus
making the investment relatively less likely in the case of either a lower
correlation or a lower degree of substitutability.
Keywords: Marketing strategy, Real options, Option interactions,
Binomial lattices.
JEL classiﬁcation: C61, G31, 032.
21 Introduction
This study investigates the value and optimal timing to invest in a pilot prod-
uct whose major purpose is to open up the market opportunity to launch a
complementary/substitute key product that will play a critical role in the
investment strategy of a corporation. The analysis is entirely based upon
the assumption that the pilot product is the required step to acquire the op-
portunity to invest in the key product. Such assumption may be supported
by one of the two following fundamental (and extreme) economic cases:
• The company is developing a family of complementary products to be
jointly launched in order to increase their overall utility to customers.
In this sense, both the pilot and key products may be seen as the ob-
ject of a broad marketing strategy whose ﬁnal aim is to optimize the
market position of a new family of complementary products;
• The company is faced with a rapidly decreasing life-cycle of products
requiring a constant development of updated versions of existing prod-
ucts in order to sustain competitiveness. Their utility to customers
decreases rapidly over time and new substitute products are needed to
revitalize their utility.
Under this scheme, the main purpose of the paper is to determine the
value and the optimal rule to invest in the pilot product as well as the optimal
investment policy for the key product.
Real life evidence oﬀers many examples of this business case. Generally
speaking, it applies to each situation where a company implements a strategy
of product-line diversiﬁcation based on sound capital investments in a new
technology/area characterized by considerable market uncertainty. In such
cases, a pilot product based on a reduced scale investment allows the company
to test the market in order to better understand some critical aspects such as
the demand potential, the competitive reaction and a feasible target price.
It is usually right before the completion of the late and most R&D inten-
sive stage that particularly valuable marketing options are considered. These
typically include: Options to enter new geographical markets, contingent on
the success of the initial target market; options to create product line exten-
sions and get new applications on the same product, contingent on the initial
success of the base version; options to develop and launch new products after
the pilot one has proven to be successful.
3Recently, other Authors have addressed the same issue. An early con-
tribution was provided by Trigeorgis (1993) who ﬁrst developed the concept
of (real) option interaction, so that the value of a portfolio of managerial
opportunities can deviate from the sum of the values of the individual op-
portunities. Pope and Stark (1997) model the ﬁrm’s value as a portfolio of
two major options: the option to use and the option to invest in new pro-
duction capacity. The ﬁrst type of option is mainly meant to realize the
option value whereas the second one is mainly utilized to develop new option
value. Also Childs, Mauer and Ott (2000), with the purpose of analyzing
the interaction between investment and ﬁnancing decisions, propose a model
for evaluating a ﬁrm’s growth option assuming that this option depends on
an asset whose value is correlated with the asset in place. Other contribu-
tions have been given by Abel, Dixit, Eberly and Pindyck (1996) and by
Kandell and Pearson (2002), who study the eﬀect of (partial) reversibility
on the value of the investment project and on the investment policy under
diﬀerent market situations, ranging from perfect competition to monopoly,
through oligopoly. As far as technology investment is concerned, Grenadier
and Weiss (1997) and Huisman and Kort (2003) present a model to incor-
porate into the option to invest in the current technology, the value of the
option to invest in future, better technologies, which may replace current
technologies, also bearing in mind a competitive environment. The dynam-
ics of R&D investment have been studied in a contingent claim framework by
Childs and Triantis (1999), who provide a model incorporating the possibil-
ity to invest in many competing projects at an early stage, allowing only one
of them to prevail. Also Schwartz and Moon (2000) address the problem of
R&D investment, by modelling a multistage investment, taking into account
the risk of failure in the research process.
In contrast with the above-mentioned approaches, we concentrate on the
marketing stage, explicitly modelling the eﬀect of complementarity/substitution
between products and the eﬀect of a transition from a monopolistic to a com-
petitive market on both the value of the project and on the investment policy.
Moreover we provide a diﬀerent numerical methodology and a diﬀerent per-
spective for analyzing the results, by comparing the investment thresholds
for the diﬀerent real options.
The next section of this paper describes some business cases involving
a pilot project/product and a main project/product. The (gross) values
of the two projects are diﬀerent but correlated, and the two projects are,
from a strategic viewpoint, either complementary or substitute. Section 3
introduces notations and discusses the model, deriving both the valuation
formula for the option to launch the pilot project and the one for the main
project. In Section 4 we present a numerical method to evaluate these options
4and the optimal investment policy and then we discuss numerical results.
Section 5 presents two possible real-life applications of the model introduced
in this paper. We relegate proof and derivation of the valuation formulas
to Appendix A. Details of the numerical method used in this paper are
presented in Appendix B.
2 Flexibility options, complementarity and
substitutability among diﬀerent products
The problem we address in this paper can be outlined as follows: a company
is evaluating the opportunity to launch a pilot product called “Minprox”
which is a necessary step for opening up the opportunity to launch a key
product, called “Newprox”. The completion of the investment in Minprox
not only allows the company to beneﬁt from the product potential itself,
but also gives the option to conclude the investment program for Newprox.
Therefore, Minprox is the necessary bridge leading to the key product. We
assume that the most relevant uncertainty driving the above options is due to
the amount of units sold.1 Two diﬀerent (but correlated) stochastic processes
model the expected units sold of the two products.
The present work also considers the problem of Newprox’s patent expiry,
and, more generally, any other ﬁnite horizon maturity due to exogenous rea-
sons, and the related change in the market structure as far as competition is
concerned. This assumption limits the time value of the embedded ﬂexibility
options and introduces an interesting concept of opportunity cost. There-
fore, the relevant question is to see how the company’s proﬁt opportunity
behaves in the light of the patent expiry. In order to account for this, we
assume that the time horizon is divided into two periods. The ﬁrst period
goes from zero to the patent expiry, when the company is assumed to be in
a monopolistic position. If Newprox were launched, an excess market return
would be gained. In the same period, the price of both products is assumed
to be constant over time. The second period goes from the patent expiry on-
wards. The company can still enter the market by optimally launching both
products, but it operates in a (perfectly) competitive environment, where
the proﬁt of the marginal ﬁrm is null. The market price of both products
is (rapidly) reduced by competitive pressure as soon as the patent expires
and remains constant thereafter. To present a more interesting situation, we
assume that the current market for Minprox is perfectly competitive, so that
1Yet, it is straightforward to extend this model to incorporate price uncertainty, as an
alternative to uncertainty about the units sold. On this, see also footnote 7 below.
5the marginal ﬁrm invests when the NPV of Minprox is null and the option
to launch Minprox is worthless (as considered in isolation with respect to the
option to launch Newprox), as shown in Dixit and Pindyck (1994), Ch. 8.
[Figure 1 about here]
An interesting aspect worth analyzing is the complementarity and sub-
stitutability characteristics of these products in relation to the correlation
between the quantities sold for both products. At the outset, we can foresee
at least four main combinations, as described in Figure 1.
In the ﬁrst quadrant, case 1, both products are totally complementary, in
the sense that their combination increases the total utility to customers, and
their revenues are positively correlated. In such case the success of the pilot
product would certainly be a trigger to launch the key product, the positive
interaction among them being the key aspect of the decision making process.
Case 2 oﬀers an example of “cannibalization” among products. In fact,
the substitutability among products, i.e. the ability of a product to replace
another one, and the positive correlation allows the launch of the key product
only at the expense of the pilot product. Moreover, this would happen under
the same scenario (i.e, best-best or worst-worst case), thus increasing the
opportunity cost of the launch of the key product.
In the third case the company would experience a diversiﬁcation eﬀect.
Since the two products are complementary, the negative correlation allows
the company to reduce its business risk by using one product as a hedge that
limits the downward potential in case the other one falls under the worst
scenario.
Lastly, the fourth case could describe the rapidly-evolving landscape of
highly competitive industries where new versions of (possibly) the same prod-
ucts are needed in order to stay at the cutting edge of technological break-
through.
This intuition can be enriched by considering how the optimal investment
policy of the ﬁrm regarding the two products is related to the to diﬀerent
combinations of the two attributes, as it is shown in Figure 2. Two major
rules appear relevant:
• A weaker (negative) correlation and a higher degree of complemen-
tarity among products lead the ﬁrm to implement the investment in
Minprox with relatively lower expected cash ﬂows. This is mainly due
to the relatively low opportunity cost in launching the key product that
does not cannibalize the pilot product and works better under diﬀerent
scenarios.
6• A stronger (positive) correlation among products and a stronger sub-
stitution eﬀect require a relatively higher amount of expected sales of
Minprox before launching it. In such a case, the decision to invest must
be based on a higher intrinsic value of the whole project that compen-
sates for the higher opportunity cost due to the more likely loss of sales
of Minprox.
The above is quite obvious as far as the decision about Newprox is con-
cerned, following the launch of Minprox has taken place. It is far less obvious
where the investment policy for both products is concerned. These intuitive
concepts will be conﬁrmed by numerical analysis and will serve as a basis of
the application of the valuation model to real-life business cases.
Intuition is of little help when considering the cases where: (a) comple-
mentary products are positively correlated; and (b) perfectly substitutable
products are negatively correlated. In these cases, numerical results are
needed to address the problem.
Next, we provide two real life examples/applications for the basic intu-
ition underlying the model: one from the pharmaceutical (complementary
products) and one from the information technology (IT) industry (substitu-
tive products).
[Figure 2 about here]
2.1 The Pharmaceutical industry and the complemen-
tarity among products
An example of complementary products can be taken from the pharmaceuti-
cal industry. As will be clearer later, one important driver of a pharmaceuti-
cal company’s likely future success is the number of products currently under
active research and development. In particular, the competitive dimension in
the pharmaceutical industry is based upon the concept of “families of prod-
ucts”, meaning that a successful marketing strategy in a given therapeutic
area requires a wide variety of products able to be jointly prescribed to cure
various forms of the base pathology. Table 1 represents the R&D pipeline,
ranking them according to the number of products, of the top ten companies.
[Table 1 about here]
With regards to this, several diseases (e.g., infections, allergies, disorders
of the central neural system etc.) are the consequence of others and may
require the joint prescription of diﬀerent products/treatments. In fact, in
7prescribing medicines, doctors are usually inﬂuenced by the brand equity of
a certain ﬁrm and the size of its portfolio of complementary products which
can be jointly prescribed in order to increase the eﬀectiveness of a certain
treatment.
The value of a pilot product in the pharmaceutical industry becomes
clearer after focusing on the entire R&D process. The R&D process of a new
pharmaceutical product is quite complex, and can be analyzed through 4 ma-
jor phases lasting approximately 8-10 years: primary research, exploratory
development, full development and marketing strategy. The two central
phases are fundamentally based on clinical trials, which represent the nec-
essary technical tests aimed at obtaining the ﬁnal approval from the FDA
commission.
[Table 2 about here]
There are three standard stages of clinical trials, whose characteristics
are described in Micalizzi (1999) and summarized in Table 2.2 Although
the failure rate decreases sharply after the ﬁrst and second phases, the large
number of patients and scope of phase three causes a large increase in costs
approaching $100 million.
This makes the third phase of clinical trials the most suitable time for op-
timizing the drug’s development process and designing alternative marketing
strategies. In fact, at this stage some ﬂexibility options become particularly
valuable. Among them, it is worth mentioning the opportunity to abandon
the R&D process for its scrap value (usually paid by biotech ﬁrms), to op-
timize the timing of the launch and to widen the spectrum of applications
by conducting more extensive trials, thus increasing the size of its market
potential.
Consequently, when entering new therapeutic areas, pharmaceutical/biotech
ﬁrms usually launch pilot products as drivers that open up market oppor-
tunities for other products. The R&D expenditures to complete and launch
the pilot product can be interpreted as a ”premium” to acquire a series of
nested options that include the opportunity to launch new versions of the
same product or new products belonging to the same family.
2.2 The Data Storage industry and the substitutability
among products
An example of substitutive products can be derived from the data storage
industry. The increased use of open-system computing environments, which
2On this, see also Schwartz and Moon (2000).
8link multiple applications, ﬁles and databases to networked computers, makes
the task of data management increasingly diﬃcult. As a result, data storage
products and services have accounted for an increasing percentage of most
organizations’ (IT) budgets and management resources.
Enterprises have historically attempted to support the management of
data requirements by directly attaching storage devices to the individual
servers on a local area network. Servers communicate in this directly-attached
environment using the Small Computer System Interface (SCSI). The major
drawbacks of such a protocol include short transportation distance, limited
conﬁguration ﬂexibility and limited connections. These limitations restrict
the capabilities of traditional storage architectures and result in a signiﬁcant
bandwidth bottleneck between storage systems and servers.
To address these limitations, ﬁbre channel technology and interconnec-
tion standards evolved in the early 1990s to enable new high-performance
connectivity. Fibre channels overcame the SCSI’s limitations and oﬀer high
performance and increased capacity needed for I/O applications. Unfortu-
nately, ﬁbre channels are an expensive storage solution, both in terms of
installation and maintenance, and are typically only implemented for use in
critical projects or enterprise applications.
For this reason many vendors are exploring iSCSI, a new protocol that
allows storage devices to be connected to a network without the need of a
ﬁbre channel, moving storage data over the Internet. In fact, iSCSI runs over
an existing Ethernet network but at speeds signiﬁcantly faster than SCSI.
IDC estimates (see Rancourt, et al. (2001)) that this market will grow at a
CAGR of over 400% between 2001 and 2005. The empirical evidence says
that ﬁrst movers who establish themselves with customers stand to beneﬁt
when the market rumps up and new technologies can be oﬀered to the already
established client base.3
Hence, the rapid evolution of such technological breakthrough leads play-
ers to move from one product to another and face a signiﬁcant substitution
eﬀect that cannibalizes the existing products in favor of the new and better
performing technologies. Pilot products become key in these cases to let the
ﬁrm acquire an initial client-base to be shifted across to the next technologies.
3 The valuation model
As a general valuation procedure, we will start by calculating the present
value of Newprox (V ) and Minprox (W) as a function of units sold (x and
3IDC estimates the market will be almost $2.5 million by 2005 (see Rancourt, et al.
(2001)).
9y, respectively). Then, we calculate the value of the opportunity to invest
in Newprox (F(V )) as a single product (assuming that Minprox has already
been launched), considering that the company can beneﬁt from the optimal
timing to invest due to the uncertainty over the units sold. Therefore, we
move from the product to the portfolio perspective and consider both invest-
ment opportunities as a compound option. We will, initially, calculate the
value of the opportunity to complete the investment in Minprox as a func-
tion of Minprox units sold and of Newprox (G(V,W)). This calculation will
provide the answer to the fundamental issue of how much a pilot product is
worth, also considering its role as driver product for subsequent complemen-
tary/substitutable investment opportunities. The determination of G will
also provide the optimal rule of investment in Minprox (W ∗(V )) as the value
of Newprox changes, as well as the optimal investment rule in Newprox (V ∗).
In what follows, we will assume that both investment projects are all
equity ﬁnanced, i.e., we will not explore how the cost of capital inﬂuences
the value of the options and the investment policy.
3.1 The value of the assets
In this section, we will derive the value of Newprox denoted V , at time t,
as a function of X(t), the sales of Newprox.4 The analysis is enriched by
the presence of a patent on Newprox: before the expiry of the patent, the
ﬁrm can obtain extra proﬁts from the product because of a monopolistic
position; after the patent’s expiry, the extra proﬁts are worn away by perfect
competition. The patent expires in T years.
We will also derive the value of Minprox, denoted W, as the present value
at the time of its launch of the cash ﬂows from the sales of this product, Y (t).
To keep the analysis reasonably simple, we will assume that there is no patent
for Minprox.5 Since we assume the ﬁnancial markets to be suﬃciently rich,
so that the uncertainties about Minprox and Newprox are spanned by other
traded securities, we will describe the relevant state variables of the model
under the equilibrium martingale measure. Let Y (t), the quantity of Minprox
4In the case of a pharmaceutical product, V is the value of the product when the last
phase of clinical trials is successfully performed or the FDA approve the product. It is
reasonable to assume that the successful event is independent of the sales of both products
and hence of market risk. If we assume that the probability of success, denoted π, is known
and time-independent, then the value of the product (before the outcome of the clinical
trial is known or FDA approval is obtained) is replaced by πV . This line of reasoning can
also be applied to other R&D projects.
5Otherwise, we could simply carry out for Minprox the same analysis proposed for
Newprox.
10sold at t, be a variable following a geometric Brownian motion:
dY (t)
Y (t)
= µdt + ζdZy(t), Y (0) = y (3.1)
where µ is the (risk-adjusted; i.e., net of the risk premium) drift of the sales
of Minprox and ζ is the volatility. Let X(t), the quantity of Newprox sold at
time t, be a stochastic process given by the solution of the following equation:
dX(t)
X(t)




ν1 if t < T
ν2 if t ≥ T
σ(t) =
(
σ1 if t < T
σ2 if t ≥ T.
(Also the drift of Newprox is net of the relevant risk premium.) This is
to model a possibly diﬀerent (lower) growth rate and a diﬀerent (lower)
uncertainty on sales of Newprox when the patent expires.
Let E[dZx(t)dZy(t)] = γdt and µ,ν2 < r in order to ensure a ﬁnite funda-
mental value for both investment projects. In such an analysis, γ will then
represent the correlation among the increment in sales of the two products.
The value of Newprox is the sum of two components: the present value
of the cash ﬂows prior to patent expiry, T, plus the present value of the cash
ﬂows after T. During the ﬁrst phase, in [0,T], the ﬁrm is in a monopolistic
position. In this time period there could be value in waiting for more fa-
vorable market conditions before launching the key product. In the second
phase, after the patent expiry, Newprox6 can also be sold by competitors
and the monopolistic market turns into a competitive one. For simplicity,
we assume that after T any ﬁrm can enter the market and the competition
is perfect. Hence, after T, the analysis will follow Dixit and Pindycks’ model
(see Dixit and Pindyck (1994), Ch. 8). Since all competitors in this mar-
ket/niche face the same risk, according to Dixit and Pindycks’ model, perfect
competition and equilibrium put an upper boundary on the price of the prod-
uct, so that, as long as the price ﬂuctuates below the boundary, no new ﬁrm
can enter the market and, as soon as the price touches (from below) the
boundary, a new ﬁrm can enter changing the supply curve for this product
and reducing its price. Hence, the upper boundary is a reﬂecting barrier for
the stochastic process of pricing. Let p denote the unit price for Newprox.
Given an inverse demand function p = p(x), the upper reﬂecting barrier for
price corresponds to an upper boundary for product sales, denoted κ. This
6Or, in the pharmaceutical case, a product based on the same formula.
11means that, after T, the competitive pressure reduces the market share of
our ﬁrm. κ is a reﬂecting barrier for X(t); that is, X(t) reaching κ represents
a signal that leads a new ﬁrm to enter. As soon as this happens, Newprox’s
sales drop below κ. Since in perfect competition a ﬁrm cannot signiﬁcantly
aﬀect the total supply and act as a price taker, with no loss of generality we
may assume that, after T, from the perspective of our ﬁrm, price is given
and settled in competitive equilibrium. Moreover, since before T our ﬁrm is
in a monopolistic position with respect to Newprox, we assume that price p
is a constant and that the product is sold at a premium, so that when the
patent expires, the price of Newprox is reduced by a ﬁxed percentage (1−λ),
0 < λ < 1.
To summarize, in this model, before T price is p, after T price is λp.
For diﬀerent reasons, the price is given in both time periods. The above
assumptions permit us to model our project assuming that sales are the
source of uncertainty, both before and after T.7
Let Φ denote the present value of the cash ﬂows8 in the ﬁrst phase.




δ1 if t < T
0 if t ≥ T.
(3.3)
Φ(x,t) is a decreasing and continuous function of t.




ψ1(x,t) if t < T
ψ2(x) if t ≥ T.
(3.4)





























7 Implicit in the above discussion is the possibility to extend the model in order to
accommodate price uncertainty instead of quantity uncertainty, as in Dixit and Pindyck
(1994), Ch. 8.
8If variable costs are considered, p is the marginal rate of contribution (or unit cash
ﬂow) of Newprox. The same can be said for q, the price of Minprox.
9In what follows, we assume that ν1 6= r. If r = ν1, we just need to replace Φ(x,t) =
px(T − t) if t < T in Equation (3.3).



































ψ1(x,t) is the present value at t < T of ψ2(x,t), the value of the cash ﬂows













% κ if x ≥ κ.
(3.7)
The value of Newprox, at (x,t) is:
V (x,t) = Φ(x,t) + Ψ(x,t). (3.8)
Since there is no patent on Minprox, this market is competitive. Follow-
ing the above discussion on perfect competition, given an inverse demand
function for Minprox, our ﬁrm takes the price of Minprox as a constant, q.
Hence, W, the present value of cash ﬂows from Minprox, can be found by
applying the same model used for Newprox after the expiry of the patent.
Given θ, the reﬂecting barrier for the stochastic process of Minprox sales, the
value of Minprox at (y,t) is the expectation of the present value of the cash













ϕ θ if y ≥ θ.
(3.9)
















ζ2 > 1. (3.10)
Note that, if θ is very large (θ → ∞), this model can be used also to describe
absence of competition for Minprox.
133.2 The value of the option to launch the key product
In this section we will derive the value of the option to launch Newprox.
Let F be the value of the investment opportunity in Newprox. Since
the option to launch the key product is exercised by giving up a share η of
the business in Minprox, F is a function of V (X(t),t), W(Y (t)) and of time
t, because as the patent approaches its maturity, the value of delaying the
investment declines. η = 1 implies that Newprox is a substitute for Minprox,
whereas η = 0 means that Newprox is a complementary product for Minprox.







−r(τ−t) (V (Xτ,τ) − IV − ηW(Yτ))
	
(3.11)
where IV is the investment cost,10 and τ ≥ t is a stopping time with regards
to the information on the state variables. According to (3.11), the ﬁrm faces
the choice of the optimal time to invest in Newprox, and F is the value
function of this problem.
By standard arguments (see Dixit and Pindyck (1994), p. 128 et ss),
there is a waiting region CN, deﬁned as
CN = {(x,y,t) | F(x,y,t) > V (x,t) − IV − ηW(y)}
where it is optimal to wait to launch Newprox, and a region SN = R3
++\CN
where it is optimal to invest. The continuation (and the stopping) region is
determined as a part of the solution of (3.11). We denote ΩN = ∂CN the
frontier of CN. ΩN is a surface in R3
++.



























The solution of problem (3.11) satisﬁes conditions11
LF(x,y,t) = 0 (x,y,t) ∈ CN (3.12a)
F(x,y,t) = V (x,t) − IV − ηW(y) (x,y,t) ∈ ΩN (3.12b)
Fx(x,y,t) = Vx(x,t) (x,y,t) ∈ ΩN (3.12c)
Fy(x,y,t) = −ηWy(y) (x,y,t) ∈ ΩN (3.12d)
F(0,y,t) = 0 for all t (3.12e)
10In the pharmaceutical case, IV is the cost of the last phase of clinical trials, whereas,
in the IT case, it is the cost of the new technology.
11This is the Veriﬁcation Theorem (see Brekke and Øksendal (1991) and Øksendal
(1998)).
14where subscripts of F denote partial derivatives.
Problem (3.12) cannot be solved analytically. Some numerical methods
are needed to obtain both the value of the investment opportunity F(x,y,t)
and the frontier ΩN. We postpone the analysis until Section 4.
Nevertheless, an analytical solution can be found if t ≥ T, and η =
0. Actually, in this case V (x,t) = ψ(x) according to Equation (3.7) and
the solution is independent on time and on y, F(x). Hence, the unknown
threshold is x∗































Ax% for x < x∗










and κ = x∗. In fact, since κ is a reﬂecting barrier, x∗ cannot be higher than
κ to make the model meaningful. Hence, F(x) ≤ 0. Moreover, since F(x) is
the value of an opportunity, it cannot be negative: F(x) ≥ 0. This implies
that F(x) = 0, that is A = 0 and κ = x∗. Following Dixit and Pindyck
(1994), p. 252 et ss. (under slightly diﬀerent hypotheses), this result has two
implications: the option to invest after the expiry of the patent is worthless
and the ﬁrm enters the market only if X(t) reaches the ceiling κ; the value
of κ depends on the investment cost of the project, as can be easily observed
in Equation (3.14). This means that, after patent expiry, also our ﬁrm obeys
the (optimal) rule of investing only when the sales hit the level κ and the
option to defer the launch of the key product is worthless (A ≡ 0) and so
F ≡ 0 ≡ ψ2(x
∗) − IV :
12In real world cases, the investment cost after T is generally lower than IV ; hence, also
the investment threshold to enter the market becomes lower after patent expiry. In what
follows, for the sake of simplicity, we keep IV constant.
15after patent expiry there is no value in waiting nor in investing in Newprox.
3.3 The value of the option to launch a pilot product
In this section we propose a model to evaluate the option to invest in Minprox.
The value of this opportunity depends both on W, the present value of the
cash ﬂows given by Minprox, and F, the value of the option to launch the
key product.
The cost of the investment in Minprox, denoted IW, is assumed to be
constant,13 and is the exercise price of the option to launch the pilot product
in order to obtain the “right” to launch Newprox. The ﬁrm’s investment op-
portunity, considering both products, is an American-type compound option
with two underlying assets, V and W and a payoﬀ given by two components:
the net present value of Minprox, and the value of the option to invest in
Newprox.
Let G denote the option to invest in Minprox. G is given by selecting the







−r(τ−t) (W(Yτ) − IW + F(Xτ,Yτ,τ))
	
. (3.15)
The continuation region for this problem is
CM = {(x,y,t) | G(x,y,t) > W(y) − IW + F(x,y,t)}
where it is optimal to postpone the investment in Minprox and a stopping
region SM = R3
++\CM. Hence, there is an unknown investment threshold
ΩM = ∂CM given by the frontier of CM.
The solution to problem (3.15) is characterized by conditions
LG(x,y,t) = 0 (x,y,t) ∈ CM (3.16a)
G(x,y,t) = W(y) − IW + F(x,y,t) (x,y,t) ∈ ΩM (3.16b)
Gx(x,y,t) = Fx(x,y,t) (x,y,t) ∈ ΩM (3.16c)
Gy(x,y,t) = Wy(y) (x,y,t) ∈ ΩM. (3.16d)
The optimal threshold, ΩM, is given as part of the solution. Problem (3.16)
can not be solved analytically. In the next section, we will provide a diﬀerent
approach to solving Problem (3.16) numerically.
13In the pharmaceutical case, IW is given by the last stage of clinical trials needed to
obtain the approval for the launch of the product whereas in the data storage industry
IW can be thought of as the capital investment needed to complete the deployment of the
communication network.
16In what remains of this section, we will analyze two interesting cases:
x = 0 and η = 0; and y = 0.
First, let x = 0 and η = 0. This is the case when there is only the
pilot product. Since the value of the option to launch the pilot product is a
function only of y and is independent of time, then we denote it G(y). Hence,





2Gyy + µyGy − rG = 0 (3.17a)
G(y
∗) = W(y




G(0) = 0 (3.17d)
where y∗ is the (unknown) free boundary when x = 0. Applying the usual
methods we have
G(0,y) = G(y) =
(
Myϕ for y < y∗
W(y) − IW for y ≥ y∗
where ϕ is deﬁned in Equation (3.10), and, as in the analysis of the option







IW = θ, M = 0, W(y
∗) − IW = 0 :
the option to invest in Minprox is always worthless, so there is no point in
waiting. Moreover, the net present value of Minprox cash ﬂows is zero at
the investment threshold, so there is no point in launching Minprox per se.
Hence, the only incentive for a ﬁrm to enter this market is the subsequent
opportunity to launch a main product (Newprox) starting from Minprox.
On the other hand, let y = 0. In this case, since the value of the option
is a function of x and t, we denote it G(x,t). Since it has been assumed that
Minprox is a necessary step to obtain the opportunity to invest in Newprox,
for some values x 6= 0 it could be worth investing in Minprox, even if this






2Gxx + ν(t)xGx + Gt − rG = 0 (3.18a)
G(0,t) = 0 (3.18b)
G(x
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t is the (unknown) boundary. This problem must be solved numeri-
cally. Nevertheless, if t ≥ T, G does not depend on t any more (Gt = 0), and
F ≡ 0 from problem (3.13). Hence, the solution to (3.18) is G(x,0,t) = 0 at
any x, because it is an option on a worthless option which is costly (IW) to
obtain.
4 Numerical analysis
In this section we provide a numerical solution of problems (3.11) and (3.15)
employing a log-transformed binomial lattice approximation of the diﬀusions
of the state variables, according to Gamba and Trigeorgis (2002). This ap-
proach proves to be more eﬃcient than other lattice methods, such as Boyle,
Evnine and Gibbs (1989) and Ekvall (1996), as far as multidimensional ge-
ometric Brownian motion processes are concerned. This feature of the log-
transformed binomial lattice approximation is extremely important in this
contest, since the analysis below is computationally intensive. An outline
of this lattice approach and of the valuation procedure is described in Ap-
pendix B.
We also provide a description of G and F as a function of x and y, for
diﬀerent values of the model parameters, in order to describe how the value of
the investment project, the value of the option to invest, and the investment
decision rule change as a function of parameters. This analysis is performed
by computing G(x,y,t) (and F(x,y,t)), at a speciﬁc time t, in a regular grid
within the rectangle [xmin,xmax] × [ymin,ymax].14
As far as the calculation of the free-boundaries is concerned, the curves
are obtained by searching an approximate 0-level sections of G(x,y,t) −
W(y) − IW + F(x,y,t).15 In fact, the search for exact 0-level curve is
very diﬃcult because the exact 0-level curve degenerates in a region in
[xmin,xmax] × [ymin,ymax].
For deﬁniteness, the base case parameters are given in Table 3.
[Table 3 about here]
In Figure 3 we plot the expanded-NPV (E-NPV) of the whole project,
i.e. the value of the project including the value of the option to defer the
investment, as a function of x and y, which represent the current values of
the stochastic processes X(t) and Y (t). E-NPV is increasing both in x and
14We compute the value of F and G in a grid with 51 × 51 points, and, for each
computation, we use the log-transformed binomial lattice scheme with 40 time steps.
15In detail, the graph show an -level section for  = 0.1.
18y and at x = 0 is worthless for any y. In fact, since the market for Minprox
is in equilibrium under the hypothesis of perfect competition, the NPV is
negative when y < θ(≈ 7.62) and equal to zero when y ≥ θ.
[Figure 3 about here]
Moreover, Figure 3 shows the (time-) value of the option to delay the
investment in Minprox, computed as the diﬀerence between the E-NPV of
Minprox and the net present value of a committed investment in Minprox,
that equals W(y)+F(x,y,t)−IW, with F(x,y,t) obtained by solving problem
(3.11) numerically at the points of the grid within [xmin,xmax] × [ymin,ymax].
As expected, the option value decreases as either x or y increase (the other
one being constant).16
Lastly, in Figure 3 we plot the investment threshold for Minprox at t = 0,
i.e., the set of triples (x,y,0) in ΩM. The set below the investment threshold
(which falls in the positive orthant) is the continuation region of problem
(3.15) at t = 0, i.e., the set of (x,y,t) in CM for which it is optimal to
postpone the launch of the pilot product. The continuation region is below
the threshold because the payoﬀ of the option to launch Minprox at any
given t is an increasing function of both x and y. As we will see below, the
threshold curve for G will always have the same shape as the one illustrated
in Figure 3, so that, for high values of x, the investment is optimal even
if y is low, and viceversa. Moreover, we observe that the region is well set
within the rectangle [0,κ] × [0,θ], where κ and θ are the reﬂecting barriers
of the units sold respectively for Newprox and Minprox in the steady state
situation.
Figure 4 provides a comparison of the investment thresholds for Minprox
and Newprox at diﬀerent values of the correlation coeﬃcient among products,
γ, and at diﬀerent values of the complementarity parameter, η. We determine
the investment thresholds at γ = 0.99 ≈ 1, η = 0, η = 1 and at γ = −0.99 ≈
−1, η = 0, η = 1 and compare them to the base case. In the base case (i.e.,
η = 0.5 and γ = 0) the opportunity to invest in Newprox clearly limits the
waiting region rightwards for Minprox.
[Figure 4 about here]
On the other hand, the thresholds change for both a diﬀerent correlation
and for a diﬀerent degree of complementarity/substitutability. Let us look
ﬁrst at the impact on the thresholds due to a higher correlation. The invest-
ment threshold of Newprox is shifted leftwards and the continuation region
16The surface is irregular for smaller values of y because of a poor numerical approxi-
mation.
19for Newprox is shrunk; i.e., a lower level of expected sales of Newprox is
required to make the option exercisable. Alternatively, investment in New-
prox becomes more likely and the option value is reduced. Notably, this is
true both at η = 1 and η = 0. The size of the waiting region for Minprox is
increased and as such the option value. Since Newprox’s sales are more likely
to follow the path of Minprox’s sales, the latter need to be higher to provide
a positive “context” for the decision to invest in the entire project. In other
words, a positive correlation makes the option to delay more valuable and
investment in Minprox less likely. Again, this is true for both η = 1 and
η = 0.
In terms of the eﬀect of complementarity/substitutability, it is worth
noticing that in all of the cases shown in Figure 4, a higher degree of substi-
tutability (η = 1) among products cause each investment threshold to shift
rightwards as, coeteris paribus, a higher amount of expected sales are always
needed to oﬀset the more likely eﬀect of substitution among products.
To summarize, Figure 4 provides an insight on the impact of γ and η
on the time value of Minprox (and so, on the value of the whole project).
It shows that the time value of Minprox in the case of higher correlation
and substitutability is always higher than the case of lower correlation and
complementarity among products. Hence, the opportunities to defer the
investment in both products are increasingly valuable in a relatively more
uncertain context where the substitutability among highly correlated prod-
ucts increases the opportunity cost of launching Newprox. With reference to
Figure 2, the above analysis allows us to provide guidance also in cases where
intuition is of little help, as noted at the outset of our analysis. Lastly, corre-
lation also has an eﬀect on the probability of a joint launch of both products
(i.e., the launch is decided on the same date). A negative correlation expands
the continuation region for Newprox and shrinks the continuation region for
Minprox; i.e., it is more likely that some time will elapse after the launch of
Minprox is decided. The opposite is true for a positive correlation: it is more
likely that the launch of Minprox and the launch of Newprox will be decided
together.
The impact of a diﬀerent time to maturity of the patent on the value of
the project is remarkable as well. Figure 5 shows the results of a sensitivity
analysis of the time-to-maturity of the patent (for 20,10,5,2 years to matu-
rity) on the value of the option to delay the launch of Minprox and on the
investment threshold. As we can see, both the value of the option and the
continuation region decrease in relation to the time to maturity; i.e., as t
increases (respectively, t = 0,10,15,18), the launch of Minprox becomes less
likely. It should be stressed that this result is strictly related to the choice
of parameters.
205 Business applications
5.1 The Schering Plough case
One concrete application of the model presented in this work refers to Scher-
ing Plough and its investment strategy in the Asthma-Allergy therapeutic
area. Schering Plough has produced for approximately ten years a well-known
anti-histamine product (Claritine). Due to the success of this product, the
company enjoys a strong image in the anti-histamine area. Since Claritine’s
patent was about to expire, the company was selecting a new product that
would be able to supplant Claritine’s role as a major source of the group’s
revenues.
This is the context in which the company, in the early 1990’s, decided
to enter the asthma ﬁeld and started the development of a new product,
Asmanex, with the following key characteristics:
i) it uses the same molecule as Claritine, so that Schering Plough can
take advantage of the positive brand image built over the years, with
notable advantages especially in the uptake phase of the new product;
ii) it focuses on asthma, a therapeutic area with one of the strongest ex-
pected growth rates. In fact, the company expected gross revenues to
reach one billion dollars over a ﬁve year period;
iii) the patent will expire in 15 years.
Asmanex is, therefore, a key product for Schering Plough, and will un-
derpin the company’s development strategy for the next decade. Asmanex,
however, poses two basic problems.
The ﬁrst problem is of a marketing nature. Few of the allergy symptoms
can be jointly treated with asthma pathologies, and this weakens the rela-
tionship between the two products. Moreover, although the product contains
the same molecule as Claritine, the asthma pathology is diﬀerent from al-
lergy, and Schering Plough does not have a signiﬁcant experience in asthma
(currently, Glaxo Wellcome and Astra are the major competitors with signif-
icant experience in the area of asthma pathologies). Consequently, Schering
Plough is faced with the challenge of bridging the gap between Claritine and
Asmanex so as to associate the use of Asmanex with other products of the
same therapeutic area.
The second problem is related to the costly and irreversible investment
due to the experimentation program required by the FDA. The company
is required to conduct tests on approximately 10,000 patients, at a cost of
21nearly $5,000 each. The present value of the total investment, including
ﬁxed costs due to facilities, amounts to approximately $275 million.
One feasible answer to the above problems lies in a product designed
to treat nasal congestion due to allergies, Nasonex. Nasonex requires fairly
contained ﬁxed costs since the experimentation phase will require tests on
2,000 patients for a period of a few months. Thanks Nasonex the company
will be able to manage both problems. In particular, Schering Plough bases
its marketing strategy upon the following key success factors:
a) pointing out the link between nasal congestion due to allergy and
asthma;
b) adopting a portfolio strategy based on complementary products;
c) actively managing the products’ life cycle.
In particular, Nasonex would underline the continuity of investments in
the company image and would represent a bridge between allergy and asthma.
In fact, the company would emphasize that asthma is nothing more than the
result of a poorly cured or an incurable allergy. In this way, Nasonex would
have the characteristics to be jointly prescribed with Asmanex, and therefore
would become the mechanism through which Schering Plough can actively
manage the transition phase between the two pathologies.
Having said that, the valuation model presented in this work ﬁts with the
business case of Schering Plough and answers two fundamental questions:
1. what is the value and the optimal rule to invest in the clinical trials of
Asmanex (key product)?
2. how valuable is Nasonex as a pilot product and as a required stage to
implement a marketing strategy of presenting Nasonex and Asmanex
as complementary products?
The correlation between Nasonex and Asmanex is expected to be fairly
positive, due to the continuity of the asthma and allergy pathologies. Hence,
the current case may belong to Case 1 of Table 1.
5.2 The Adaptec case
Adaptec is a leading supplier of storage access solutions deriving 80% of its
revenues from Small Computer Systems Interface (SCSI) products, a market
in which Adaptec is one of the leaders. This market relationship has been key
to the company’s success and is expected to drive revenue in the short-term.
22As explained before, the SCSI technology is being replaced by ﬁber chan-
nel in some applications. Adaptec was late in introducing its ﬁbre channel
products and has not enjoyed the same market leadership with them as it did
with SCSI. However, the company has made several pilot investments in the
ﬁber protocol, analyzed several ways to overcome the constraints of the SCSI
technology and explored the real upside potential of the high performance
storage connectivity market.
These investments are now becoming even more strategic. In fact, as ﬁbre
channel technology continues to take market share from SCSI, Adaptec runs
the risk of declining revenues.
In order to overcome this risk, the company is now turning its attention
to the next cutting edge technology, the iSCSI (i.e., the standard SCSI where
storage data is moved over the Internet), which is considered a key investment
program. iSCSI-based Storage Area Network (SAN) is expected to be a
disruptive technology, which has the potential to replace ﬁber channel-based
SANs. Due to the considerable expected growth rate of iSCSI over the next
ﬁve years (400% CAGR), Adaptec’s business unit dedicated to SAN products
could experience huge growth over the next few years. If IDC estimates are
correct, revenues in this segment will oﬀset the diminished income due to the
shift away from SCSI technology.
An initial sign of a concrete interest in the iSCSI segment is the recent ac-
quisition of Platys (approximately $150 million in value), a small player fully
dedicated to the development of the iSCSI protocol. By doing so Adaptec
has strategically entered the iSCSI market and is now positioned with Cisco
and NetApp in developing the new protocol.
Design lock-in is what drives Adaptec’s new market. Once an Original
Equipment Manufacturers (OEM) decides on a Host Bus Adaptor (HBA) or
other card, many engineers work for up to a year writing the drivers and
certifying the HBA. This commitment of time and eﬀort locks an OEM into
certain devices. When a diﬀerent vendor comes along with a new device, the
new capabilities have to be weighted against the time and eﬀort required to
certify the new device. When awarded, design wins usually lock-in an OEM
for ﬁve years. By winning contracts with major hardware vendors, Adaptec
will ﬁrmly position itself as a player in this market while validating its Platys
acquisition and technology.
The key risk is the timing and degree of iSCSI adoption and Adaptec’s
execution. In fact, iSCSI success is not assured as its advantages over the
incumbent Fibre Channel protocol are not as compelling as previous technol-
ogy transitions. In particular, in the iSCSI adapter market, the competitive
landscape is shaping up to be quite tough with almost all the major players
working actively in this space (e.g., Intel, Emulex and QLogic).
23Our model may help interpret the investment in the Fiber Channel seg-
ment as being a pilot project designed to ramp up the company’s ability to
serve the demand for high performance storage connectivity. While doing
so, Adaptec may acquire critical information on such demand and on how
manageable the transition from ﬁber to iSCSI is. Consequently, the large in-
vestment in the iSCSI protocol, as a key investment area, may be optimized
over time and gradually implemented as the market demand becomes ready
to be shifted away from ﬁber.
Such an analysis leads us to the conclusion that the current Adaptec
case is a good example of Case 4 of Table 1. In fact, the high degree of
substitutability is associated with an expectation of a negative correlation
among products. This is mainly supported by the empirical evidence of
the last few years where breakthrough technologies have shown a negative
correlation with the incumbent products.
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26A Proofs
We will verify that
V (x,t) = Φ(x,t) + Ψ(x,t)
with Φ(x,t) from equation (3.3) and Ψ(x,t) from equation (3.4). To derive
Ψ analytically, we will discuss separately the cases t < T and t ≥ T.
Let ﬁrst consider the value of the revenues after the expiration of the
patent: t ≥ T. In this case the horizon is inﬁnite. The present value of the













% κ if x ≥ κ
(A.1)



























2%(% − 1) + ν2% − r = 0
as in Dixit and Pindyck (1994), pp. 255-256.



















2fxx(x) + ν2xfx(x) − rf(x) + λpx = 0 (A.4)






where % is deﬁned in (A.2). Since κ is a reﬂecting barrier, ψ2(x) in (A.5)


















i.e., the value of ψ2 at κ. Equations (A.5), (A.6) and (A.7) considered alto-
gether provide Equation (A.1).
Next, consider t < T. In this case, the value at (x,t) of the revenues
obtained after the expiry is the expectation at (x,t) of the value at T, since
at that date the (inﬁnite horizon) steady state is immediately reached. Hence,












































To prove (A.8), let f(z) be the probability density function of the standard



























































































































































that is, Equation (A.8).




ψ1(x,t) if t < T
ψ2(x) if t ≥ T.
with ψ1(xt,t) from Equation (A.8) and ψ2(xt) from Equation (A.1).
29B Numerical methods
We summarize here the main features of the improved log-transformed bi-
nomial lattice approach, suited to price options with payoﬀs depending on a
multidimensional log-Normal diﬀusion, as proposed in Gamba and Trigeor-
gis (2002). We specialize it to the two-dimensional setting of our valuation
problem. The log-transformed method maintains the stability feature of the
one-dimensional approach proposed by Trigeorgis (1991).
Given the dynamics of sales
dX(t) = ν1X(t)dt + σ1X(t)dZx(t)
dY (t) = µY (t)dt + ζY (t)dZy(t)
(B.1)
with correlation coeﬃcient γ, we take b X = logX and b Y = logY , so that
d b X(t) = a1dt + σ1dZx(t),
db Y (t) = a2dt + ζdZy(t),
(B.2)
where a1 = ν1 − σ2































































W is a matrix providing a change of coordinates of the plane b X-b Y so that
the dynamics are uncorrelated. Hence, denoting y> = (b x, b y) the vector of
variables transformed through W, the diﬀusion process of y is
db x = A1dt + B11dZ1 + B12dZ2
db y = A2dt + B21dZ1 + B22dZ2
30where B = (Bij) = W >b and A = W >a. The covariance matrix of dy is
dydy> = Λdt; that is, db x and db y are uncorrelated.
We approximate (db x,db y) with a discrete process: given the time interval
[0,T] and n, we consider subintervals of width ∆t = T/n. The discrete
process is (e x, e y) with dynamics
e x(t) = e x(t − ∆t) + `1U1(t)
e y(t) = e y(t − ∆t) + `2U2(t)
(B.3)
t = 1,...,n where (U1,U2) is a bi-variate i.i.d. binomial random variable:
(U1,U2) =

   
   






i=1 pi = 1. We assign parameters
ki = Ai∆t, `i =
q
ρi∆t + k2
i, Li = ki/`i








1 if state variable i jumps up
−1 if state variable i jumps down
for i = 1,2, and Γ12(s) = Γ1(s)Γ2(s).
For the discrete-time process, we have the following:
E[∆e yi] = ki = Ai∆t i = 1,2




i = ρi∆t i = 1,2
Cov[∆e y1,∆e y2] = 0.
Hence, this discrete process is consistent with the continuous process for any
time step.
We want to evaluate an option whose payoﬀ, Π, is a non-linear function





31We can make the derivative security dependent on y> = (b x, b y) by changing
the payoﬀ function as follows:





where (Wy(t))i is the i-th component of vector Wy(t). The risk-neutral price
of b Π, denoted b F, is equal to the risk-neutral price of Π, denoted F (we refer
to Gamba and Trigeorgis (2002) for details):
b F (b x(t),b y(t)) = e
r(T−t)b E
h
b Π(b x(T),b y(T))
i
= e
r(T−t)E[Π(X(T),Y (T))] = F(X(t),Y (t))
where b E[·] denotes the risk neutral expectation with respect the martingale
probability of the process {(b x, b y)}, and E[·] is the expectation w.r.t. the
martingale probability of the process {(X,Y )}.
In order to compute the value of the option to launch the two products
when a closed form formula is not available, we exploit the above illustrated
extended log-transformed binomial lattice approximation of the diﬀusion in
(B.1). Hence, by approximating (b x, b y) with (e x, e y), as of (B.3), the value of
the option to launch Newprox is obtained by backward induction: at t = T
b F (e x(T),e y(T)) = max{Π1 (e x(T),e y(T)),0}
and at t < T
b F (e x(t),e y(t)) = max
n
Π1 (e x(t),e y(t)),e
−r∆te Et
h
b F (e x(t + ∆t),e y(t + ∆t))
io
where
Π1 (e x(t),e y(t)) = V (e x(t),t) − IV − ηW (e y(t))
and e Et[·] denotes conditional expectation, at t, according to discrete proba-
bility in (B.4).
The same can be done to compute the value of Minprox: at t = T
b G(e x(T),e y(T)) = max{Π2 (e x(T),e y(T)),0}
and at t < T
b G(e x(t),e y(t)) = max
n
Π1 (e x(t),e y(t)),e
−r∆te Et
h
b G(e x(t + ∆t),e y(t + ∆t))
io
where
Π2 (e x(t),e y(t)) = W (e y(t)) − IV + F (e x(t),e y(t),t).
The extension of this methodology to a multidimensional problem (with
more than two underlying assets) and more compounded options (i.e., more
interacting products/projects) is straightforward.
32Exhibits
Figure 1: Complementarity/Substitutability vs correlation
Figure 2: Complementarity/Substitutability and eﬀect on investment deci-
sions
33Table 1: R&D product status of the top 10 pharmaceutical companies ranked








1 Merck&Co 137 17 22 10 4 190
2 Hoechst 106 15 24 9 7 161
3 Novartis 82 27 33 12 5 159
4 Roche 82 21 36 10 8 157
5 Pharmacia & Upjohn 83 16 14 16 10 139
6 American Home Products 53 17 32 21 12 135
7 Lilly 84 11 12 7 0 114
8 Bristol Myers-Squibb 65 9 16 13 4 107
9 Glaxo Wellcome 56 11 25 6 4 102
10 SmithKline Beecham 45 14 19 18 6 102
(Source: Datamonitor, ADIS International, 1997)









5-7 1 2 3 1.5-2.5 12-15
% of success
at each stage
< .01% 70 % 47 % 75 % 80 % < .001%
Avg. cost
per stage ($ m) 6 12 12 100 40 170
(Source: Datamonitor, Lehman Brothers “New Drug Discovery Technologies”,
3/1997)
34Table 3: Base case parameters
r risk-free rate 0.05
µ drift of sales of Minprox 0.01
ζ volatility of sales of Minprox 0.1
ν1 drift of sales of Newprox before T 0.1
ν2 drift of sales of Newprox after T 0.02
σ1 volatility of sales of Newprox before T 0.25
σ2 volatility of sales of Newprox after T 0.15
γ correlation coeﬃcient 0
T patent expiry 20 (years)
IW capital expenditure for Minprox 30 (millions of $)
IV capital expenditure for Newprox 400 (millions of $)
p price per unit of Newprox 1 ($)
q price per unit of Minprox 0.25 ($)
λ price reduction after patent expiry 0.8
η complementarity coeﬃcient 0.5
For these parameters, % = 1.75486, φ = 2.70156, κ = 34.8711, θ = 7.62094.
35E-NPV of Minprox
(t = 0, eta = 0.5, corr = 0)





















G(x,y,0) - W(y) - F(x,y,0) + Iw
eta = 0.5, corr = 0
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Figure 3: Base case (η = 0.5,γ = 0), at t = 0 (from top): expanded NPV
of Minprox, G(x,y,t); value of the option to invest in Minprox; investment
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Figure 4: Comparison of trigger functions for Minprox and Newprox at dif-
ferent values of η and γ at t = 0.
37G(x,y,0) - W(y) - F(x,y,0) + Iw
eta = 0.5, corr = 0


















G(x,y,0) - W(y) - F(x,y,0) + Iw
eta = 0.5, corr = 0, t = 10
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eta = 0.5, corr = 0, t = 15


















G(x,y,0) - W(y) - F(x,y,0) + Iw
eta = 0.5, corr = 0, t = 18
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Figure 5: Sensitivity analysis on t (η = 0.5 and γ = 0).
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